Clinical Trial Update: A Study to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]AZD9833 [Phase 1]

View source ↗

Summary

This Phase 1 trial completed and assessed the mass balance recovery, metabolite profile, and metabolite identification of radiolabeled AZD9833 in patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AZD9833 (AZD9833)

Snippet

Sponsor: AstraZeneca | Conditions: ER-positive, HER2-negative Breast Cancer | Phase 1 | Status: COMPLETED